Tuberculosis and Respiratory Diseases

  • 제69권3호
  • /
  • Pages.153-162
  • /
  • 2010
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

금연

Smoking Cessation

  • 김용현 (가톨릭대학교 의과대학 내과학교실) ;
  • 이상학 (가톨릭대학교 의과대학 내과학교실)
  • Kim, Yong-Hyun (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Sang-Haak (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 투고 : 2010.05.27
  • 심사 : 2010.06.01
  • 발행 : 2010.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Smoking is the most important risk factor of many pulmonary diseases, including chronic obstructive pulmonary disease and lung cancer, cardiovascular disorders and other malignancies. Therefore, smoking cessation is a practical way to prevent and treat smoking-related diseases. Also, the clinicians who care the patients with smoking-related disease should pay attention to it. This article reviews briefly recent publications focused on the influence of smoking cessation in some smoking-related diseases and strategies to improve smoking cessation such as pharmacotherapy or systemic behavioral approach programs. In addition, it reviews personalized therapy based on gene typing for smoking cessation.

키워드

참고문헌

  1. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569. https://doi.org/10.1136/bmj.b5569
  2. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from smoking in developed countries, 1950- 2000: indirect estimates from national vital statistics. 1st ed. Oxford: Oxford University Press; 1994.
  3. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123 Suppl 1:21S-49S. https://doi.org/10.1378/chest.123.1_suppl.21S
  4. Gerber Y, Rosen LJ, Goldbourt U, Benyamini Y, Drory Y; Israel Study Group on First Acute Myocardial Infarction. Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. J Am Coll Cardiol 2009;54:2382-7. https://doi.org/10.1016/j.jacc.2009.09.020
  5. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000;160:939-44. https://doi.org/10.1001/archinte.160.7.939
  6. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97. https://doi.org/10.1001/jama.290.1.86
  7. Burling TA, Singleton EG, Bigelow GE, Baile WF, Gottlieb SH. Smoking following myocardial infarction: a critical review of the literature. Health Psychol 1984;3:83-96. https://doi.org/10.1037/0278-6133.3.1.83
  8. Lindstrom D, Sadr Azodi O, Wladis A, Tonnesen H, Linder S, Nasell H, et al. Effects of a perioperative smoking cessation intervention on postoperative complications: a randomized trial. Ann Surg 2008;248:739-45. https://doi.org/10.1097/SLA.0b013e3181889d0d
  9. Sorensen LT, Karlsmark T, Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. Ann Surg 2003;238:1-5.
  10. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002;359:114-7. https://doi.org/10.1016/S0140-6736(02)07369-5
  11. Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H. Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Arch Intern Med 2009;169:230-5. https://doi.org/10.1001/archinternmed.2008.556
  12. Myung SK, McDonnell DD, Kazinets G, Seo HG, Moskowitz JM. Effects of web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:929-37. https://doi.org/10.1001/archinternmed.2009.109
  13. Linder JA, Rigotti NA, Schneider LI, Kelley JH, Brawarsky P, Haas JS. An electronic health record-based intervention to improve tobacco treatment in primary care: a cluster-randomized controlled trial. Arch Intern Med 2009;169:781-7. https://doi.org/10.1001/archinternmed.2009.53
  14. Shea S, DuMouchel W, Bahamonde L. A meta-analysis of 16 randomized controlled trials to evaluate computer- based clinical reminder systems for preventive care in the ambulatory setting. J Am Med Inform Assoc 1996;3:399-409. https://doi.org/10.1136/jamia.1996.97084513
  15. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 2005;330:765. https://doi.org/10.1136/bmj.38398.500764.8F
  16. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598-600. https://doi.org/10.1136/bmj.39503.582396.25
  17. Van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002;324:1370. https://doi.org/10.1136/bmj.324.7350.1370
  18. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789-94. https://doi.org/10.1136/thorax.55.9.789
  19. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232.
  20. Morris JF, Temple W. Spirometric "lung age" estimation for motivating smoking cessation. Prev Med 1985;14:655-62. https://doi.org/10.1016/0091-7435(85)90085-4
  21. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009;360:699-709. https://doi.org/10.1056/NEJMsa0806819
  22. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024. https://doi.org/10.1136/bmj.b1024
  23. The Office for National Statistics (UK). Smoking-related behaviour and attitudes, 2008/09. [Internet]. London: The Office for National Statistics (UK); c2009 [cited 2010 May 20]. Available from: http://www.statistics.gov.uk/downloads/theme_health/Smoking2008-9.pdf.
  24. Taylor T, Lader D, Bryant A, Keyse L, Joloza MT. Smoking-related behaviour and attitudes, 2005. London: The Office for National Statistics (UK); 2006.
  25. Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009;169:2148-55. https://doi.org/10.1001/archinternmed.2009.426
  26. Fiore MC, Jaen CR, Baker TB. Treating tobacco use and dependence: 2008 update. Rockville: US Dept of Health and Human Services, US Public Health Service; 2008.
  27. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008;179:135-44. https://doi.org/10.1503/cmaj.070256
  28. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55. https://doi.org/10.1001/jama.296.1.47
  29. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63. https://doi.org/10.1001/jama.296.1.56
  30. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placeboand bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8. https://doi.org/10.1001/archinte.166.15.1561
  31. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7. https://doi.org/10.1001/archinte.166.15.1571
  32. Smith PM, Burgess E. Smoking cessation initiated during hospital stay for patients with coronary artery disease: a randomized controlled trial. CMAJ 2009;180:1297-303. https://doi.org/10.1503/cmaj.080862
  33. Van Spall HG, Chong A, Tu JV. Inpatient smoking-cessation counseling and all-cause mortality in patients with acute myocardial infarction. Am Heart J 2007;154:213-20. https://doi.org/10.1016/j.ahj.2007.04.012
  34. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;(1):CD003041.
  35. van Domburg RT, Meeter K, van Berkel DF, Veldkamp RF, van Herwerden LA, Bogers AJ. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol 2000;36:878-83. https://doi.org/10.1016/S0735-1097(00)00810-X
  36. Ellerbeck EF, Mahnken JD, Cupertino AP, Cox LS, Greiner KA, Mussulman LM, et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann Intern Med 2009;150:437-46. https://doi.org/10.7326/0003-4819-150-7-200904070-00003
  37. Centers for Disease Control and Prevention (CDC). Physician and other health-care professional counseling of smokers to quit--United States, 1991. MMWR Morb Mortal Wkly Rep 1993;42:854-7.
  38. Lopez-Quintero C, Crum RM, Neumark YD. Racial/ethnic disparities in report of physician-provided smoking cessation advice: analysis of the 2000 National Health Interview Survey. Am J Public Health 2006;96:2235-9. https://doi.org/10.2105/AJPH.2005.071035
  39. Ellerbeck EF, Ahluwalia JS, Jolicoeur DG, Gladden J, Mosier MC. Direct observation of smoking cessation activities in primary care practice. J Fam Pract 2001;50:688-93.
  40. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009;85:635-43. https://doi.org/10.1038/clpt.2009.19
  41. Benowitz NL, Jacob P 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994;56:483-93. https://doi.org/10.1038/clpt.1994.169
  42. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997;282:1608-14.
  43. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996;277:1010-5.
  44. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72. https://doi.org/10.1016/j.clpt.2004.02.011
  45. Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006;80:457-67. https://doi.org/10.1016/j.clpt.2006.08.011
  46. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000;58:747-55. https://doi.org/10.1124/mol.58.4.747
  47. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008;29:679-88. https://doi.org/10.1002/humu.20698
  48. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004;14:615-26. https://doi.org/10.1097/00008571-200409000-00006
  49. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 2007;9:511-8. https://doi.org/10.1080/14622200701239605
  50. Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 2006;6:115-9. https://doi.org/10.1038/sj.tpj.6500348
  51. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-5. https://doi.org/10.1038/clpt.2008.57

피인용 문헌

  1. 호흡기내과 외래로 내원한 환자들에 대한 금연프로그램의 단기간 효과 vol.71, pp.2, 2010, https://doi.org/10.4046/trd.2011.71.2.114
  2. 금연/흡연예방 프로그램의 방법에 따른 효과성 평가: 최근 3년 간 국내학술지 논문에 대한 체계적 문헌고찰 vol.30, pp.5, 2010, https://doi.org/10.14367/kjhep.2013.30.5.061
  3. 지역사회 거주 성인남성의 금연의도 관련요인 vol.26, pp.4, 2010, https://doi.org/10.12799/jkachn.2015.26.4.364